We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Colon Cancer Cells Adopt Stem Cell Characteristics to Metastasize to the Liver

By LabMedica International staff writers
Posted on 12 Jul 2015
Cancer researchers have identified an interlocked set of enzyme activities, similar to those found in stem cells, expressed in colorectal cancer (CRC) cells, which confer on these cells the enhanced cellular motility required for metastasis into the liver.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) worked with mouse models of colorectal cancer metastasis to the liver. More...
The first gene they linked to metastasis was L1. L1 family members are able to bind to a number of other proteins. As cell adhesion molecules, they often bind "homophilically" to themselves; for example L1 on one cell binding to L1 on an adjacent cell. L1 family members also bind "heterophilically" to members of the contactin or CNTN1 family. In addition, L1 family members bind to many cytoplasmic proteins such as ezrin-moesin-radixin (ERM) proteins and to various signaling molecules and proteins important in trafficking.

The investigators reported in the April 27, 2015, online edition of the journal Oncogene that L1 could confer enhanced motility and liver metastasis when expressed in CRC cells. This ability of L1-mediated metastasis was exerted by a mechanism involving ezrin and the activation of NF-kappaB target genes. Ezrin is a cytoplasmic peripheral membrane protein that functions as a protein-tyrosine kinase substrate in microvilli. As a member of the ERM protein family, ezrin serves as an intermediate between the plasma membrane and the actin cytoskeleton. It plays a key role in cell surface structure adhesion, migration, and organization and has been implicated in various human cancers.

In the present study, the investigators identified SMOC-2 (secreted modular calcium-binding matricellular protein-2) as a gene activated by L1-ezrin-NF-kappaB signaling. The induction of SMOC-2 expression in L1-expressing CRC cells was necessary for the increase in cell motility, proliferation under stress, and liver metastasis conferred by L1. SMOC-2 was localized at the bottom of normal human colonic crypts and at increased levels in CRC tissue with preferential expression in invasive areas of the tumor.

"This research," said senior author Dr. Avri Ben-Ze'ev, professor of genetics at the Weizmann Institute of Science, "provides support for the idea that as cancer develops, it also reverts—that is, some of its cells adopt a less mature, more stem-like, state that assists metastasis. Additional investigations into the interactions between SMOC-2 and other genes suggested that the human cancer cells were, indeed, taking on some qualities of stem cells. We hope that further research will point to ways of interfering with the activities of genes like SMOC-2, thus preventing this cancer from metastasizing. In addition, the expression patterns of SMOC-2 could make it an ideal marker for the early detection of human metastatic colorectal cancer."

Related Links:

Weizmann Institute of Science



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.